{"name":"Glenmark Pharmaceuticals","slug":"glenmark-pharmaceuticals","ticker":"GLENMARK.NS","exchange":"NSE","domain":"glenmarkpharma.com","description":"Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for ","hq":"Mumbai, India","founded":0,"employees":"15800","ceo":"","sector":"Dermatology / Respiratory Generics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":2340.6,"stockChange":63,"stockChangePercent":2.77,"marketCap":"$6.9B","metrics":{"revenue":1724069257.574187,"revenueGrowth":15.1,"grossMargin":70.7,"rdSpend":0,"netIncome":111224625.80711424,"cash":280935993.3662167,"dividendYield":0.22,"peRatio":61.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","indication":"Other","status":"phase_2"},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","indication":"Prevention of organ rejection in transplant patients","status":"phase_3"},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","indication":"Allergic rhinitis (seasonal and perennial)","status":"phase_3"},{"name":"GBR 900","genericName":"GBR 900","slug":"gbr-900","indication":"Other","status":"phase_1"},{"name":"GRC 27864","genericName":"GRC 27864","slug":"grc-27864","indication":"Other","status":"phase_1"},{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","indication":"Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","status":"marketed"},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","indication":"Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"marketed"},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","indication":"Atopic dermatitis","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","indication":"Atopic dermatitis (eczema) in patients ≥2 years of age","status":"phase_3"},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","indication":"Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions","status":"phase_3"}]}],"pipeline":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","phase":"marketed","mechanism":"Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.","indications":["Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","Post-traumatic inflammation and pain relief"],"catalyst":""},{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","phase":"phase_3","mechanism":"Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation.","indications":["Prevention of organ rejection in transplant patients"],"catalyst":""},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","phase":"marketed","mechanism":"Voltaren Gel is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce local inflammation and pain at the site of application.","indications":["Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","Acute pain relief from minor sprains, strains, and contusions"],"catalyst":""},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","phase":"phase_3","mechanism":"DYMISTA is a nasal spray combining azelastine (a selective H1-receptor antagonist) and fluticasone propionate (a corticosteroid) to reduce allergic rhinitis symptoms through dual anti-inflammatory and antihistamine action.","indications":["Allergic rhinitis (seasonal and perennial)"],"catalyst":""},{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","phase":"phase_3","mechanism":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","indications":["Atopic dermatitis (eczema) in patients ≥2 years of age","Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis"],"catalyst":""},{"name":"GBR 900","genericName":"GBR 900","slug":"gbr-900","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GRC 27864","genericName":"GRC 27864","slug":"grc-27864","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":["Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions"],"catalyst":""},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","phase":"phase_3","mechanism":"Protopic ointment, 0.1% works by inhibiting the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to reduce inflammation.","indications":["Atopic dermatitis","Severe psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":11,"phaseCounts":{"marketed":2,"phase_2":2,"phase_3":5,"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":1372789943.89064,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1372789943.89064},{"period":"2024-03-31","value":1215064373.94944},{"period":"2023-03-31","value":1193811449.16012},{"period":"2022-03-31","value":1271323983.4525201}],"grossProfit":875991470.42356,"grossProfitHistory":[{"period":"2025-03-31","value":875991470.42356},{"period":"2024-03-31","value":705557253.37984},{"period":"2023-03-31","value":714842654.73742},{"period":"2022-03-31","value":772350384.58898}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":167427742.40912,"operatingIncome":195119786.07458,"operatingIncomeHistory":[{"period":"2025-03-31","value":195119786.07458},{"period":"2024-03-31","value":65901736.020500004},{"period":"2023-03-31","value":112664373.56476},{"period":"2022-03-31","value":192152054.13152}],"netIncome":109345973.27078,"netIncomeHistory":[{"period":"2025-03-31","value":109345973.27078},{"period":"2024-03-31","value":-156815795.47032002},{"period":"2023-03-31","value":31040623.5763},{"period":"2022-03-31","value":98340751.46314}],"eps":37.11,"epsHistory":[{"period":"2025-03-31","value":37.11},{"period":"2024-03-31","value":-53.22},{"period":"2023-03-31","value":10.53},{"period":"2022-03-31","value":33.37}],"cash":174990294.91218,"cashHistory":[{"period":"2025-03-31","value":174990294.91218},{"period":"2024-03-31","value":173169388.4098},{"period":"2023-03-31","value":121052949.49122},{"period":"2022-03-31","value":147298042.39124}],"totalAssets":1676018652.22796,"totalLiabilities":751930271.02616,"totalDebt":258215026.58258,"equity":924127123.89334,"operatingCashflow":-86423875.4853,"operatingCashflowHistory":[{"period":"2025-03-31","value":-86423875.4853},{"period":"2024-03-31","value":-27719717.01656},{"period":"2023-03-31","value":65308273.17408},{"period":"2022-03-31","value":115774022.80648}],"capex":-78275796.64406,"capexHistory":[{"period":"2025-03-31","value":-78275796.64406},{"period":"2024-03-31","value":-93815584.20572},{"period":"2023-03-31","value":-63467316.54562},{"period":"2022-03-31","value":-82510132.64558001}],"freeCashflow":-164699672.12936,"dividendsPaid":-7356098.86108,"buybacks":null,"employees":15800,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":60090958.85594,"ebitda":76219405.58798,"period":"2025-12-31","revenue":406014948.69226,"epsBasic":14.29,"netIncome":42106622.32862,"rdExpense":null,"epsDiluted":14.28,"grossProfit":270770373.76278,"operatingIncome":74697475.70522},{"sga":null,"ebit":107964080.98736,"ebitda":122709277.87536,"period":"2025-09-30","revenue":626962638.84556,"epsBasic":21.63,"netIncome":63737784.39222,"rdExpense":null,"epsDiluted":21.62,"grossProfit":494913239.47686,"operatingIncome":231657381.45674},{"sga":null,"ebit":16061404.12296,"ebitda":29629282.6702,"period":"2025-06-30","revenue":319479231.09742,"epsBasic":1.66,"netIncome":4894632.60154,"rdExpense":null,"epsDiluted":1.66,"grossProfit":213424924.61918,"operatingIncome":47054513.07756},{"sga":null,"ebit":7799290.18964,"ebitda":20874165.37634,"period":"2025-03-31","revenue":336271107.26168,"epsBasic":null,"netIncome":485588.991,"rdExpense":null,"epsDiluted":null,"grossProfit":180365921.68416,"operatingIncome":45835110.35758},{"sga":null,"ebit":53113932.69106,"ebitda":65931184.64318,"period":"2024-12-31","revenue":344810372.41696,"epsBasic":12.33,"netIncome":36336885.26588,"rdExpense":null,"epsDiluted":12.33,"grossProfit":231585952.88258,"operatingIncome":49863306.00034},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":12.55,"netIncome":null,"rdExpense":null,"epsDiluted":12.55,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2340.6,"previousClose":2277.6,"fiftyTwoWeekHigh":2474,"fiftyTwoWeekLow":1370,"fiftyTwoWeekRange":"1370.0 - 2474.0","fiftyDayAverage":2225.46,"twoHundredDayAverage":2035.22,"beta":0.31,"enterpriseValue":6743643707.835155,"forwardPE":29.2,"priceToBook":6.89,"priceToSales":4,"enterpriseToRevenue":3.91,"enterpriseToEbitda":16.02,"pegRatio":0,"ebitda":420821670.22755843,"ebitdaMargin":24.4,"freeCashflow":0,"operatingCashflow":0,"totalDebt":127838042.6495959,"debtToEquity":12.8,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":11,"targetMeanPrice":2227.36,"targetHighPrice":2735,"targetLowPrice":1500,"dividendRate":5,"payoutRatio":0.13,"fiveYearAvgDividendYield":0.35,"exDividendDate":1759449600,"insiderHeldPercent":49,"institutionHeldPercent":26.9,"sharesOutstanding":282200809,"floatShares":141576013,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":37.81,"epsForward":80.06,"revenuePerShare":585.09,"bookValue":339.57,"officers":[{"age":55,"name":"Mr. Glenn Mario Saldanha","title":"Chairman, MD & CEO"},{"age":58,"name":"Ms. Cherylann Maria Pinto B.Pharm","title":"Executive Director of Corporate Services & Executive Director"},{"age":null,"name":"Mr. Harish Vinayak Kuber","title":"Company Secretary & Compliance Officer"},{"age":54,"name":"Mr. Alind  Sharma","title":"President and Chief Human Resources Officer"},{"age":58,"name":"Mr. Ulhas R. Dhuppad","title":"President & Head of Global Pharmaceutical Development"},{"age":null,"name":"Mr. Indrajit  Bose","title":"President & Chief Quality Officer"},{"age":null,"name":"Mr. Brijlal  Motwani","title":"President & Chief Quality Officer"},{"age":null,"name":"Mr. Alok  Malik","title":"President & Business Head of India Formulations"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://glenmarkpharma.com","phone":"91 22 4018 9999"}}